Skip to main content

Table 3 Treatment regimen in the patients with and without the event of poor treatment outcome

From: Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still’s disease

Treatment

With the eventa (n=29)

Without the event (n=42)

p-value

Initial PSL dose (mg/kg/day) at week 0, mean ± SD

0.97 ± 0.15

0.72 ± 0.23

<0.001

GC pulse at week 0, n (%)

23 (79.3)

11 (26.2)

<0.001

Additional GC pulse within 4 weeks, n (%)

17 (58.6)

0

-

Additional immunosuppressive drugs at the event of poor treatment outcome, n (%)

24 (82.8)

0

-

 MTX, n (%)

10 (34.5)

-

-

 CyA, n (%)

4 (13.8)

-

-

 Tac, n (%)

4 (13.8)

-

-

 TCZ, n (%)

2 (6.9)

-

-

 MTX + TCZ, n (%)

1 (3.4)

-

-

 CyA + TCZ

3 (10.3)

-

-

  1. GC glucocorticoid, MTX methotrexate, CyA cyclosporine, Tac tacrolimus, TCZ tocilizumab
  2. aEvent of a poor treatment outcome, which was defined as failure to achieve remission or relapse after achieving remission within 4 weeks, followed by administration of two or more rounds of GC pulse therapy or of any other immunosuppressive drugs